DWDan Wang

Dan Wang

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Dan Wang has a total of 31 co-authors. Here are the top co-authors by number of shared publications:

  • Yi Zhang

    Biotherapy Center and Cancer Center, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, China

    2 shared publications
  • Chunyi Shen

    The First Affiliated Hospital of Zhengzhou University 1 Biotherapy Center and Cancer Center Zhengzhou, China

    1 shared publication
  • Guohui Qin

    Biotherapy Center, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, China; Henan Key Laboratory for Tumor Immunology and Biotherapy, Zhengzhou, China

    1 shared publication
  • Hongye Li

    The Key Laboratory of Molecular Biology of Crop Pathogens and Insects of Ministry of Agriculture, The Key Laboratory of Biology of Crop Pathogens and Insects of Zhejiang Province, Institute of Biotechnology, Zhejiang University, Hangzhou, China

    1 shared publication
  • Jiahao Yang

    Department of Orthopaedic Surgery

    1 shared publication
  • Jianmin Huang

    Ant Group, Hangzhou, China

    1 shared publication

Latest Publications

  • Open Access

    A short peptide LINC00665_18aa encoded by lncRNA LINC00665 suppresses the proliferation and migration of osteosarcoma cells through the regulation of the CREB1/RPS6KA3 interaction

    by Junwei Pan, Ming Liu, Xiaozong Duan, Dan Wang

    Long noncoding RNAs (lncRNAs) encompass short open reading frames (sORFs) that can be translated into small peptides. Here, we investigated the encoding potential of lncRNA LINC00665 in osteosarcoma (OS) cells. Bioinformatic analyses were utilized to predict the lncRNAs with encoding potential in human U2OS cells. Protein expression was assessed by an immunoblotting or immunofluorescence method. Cell viability was assessed by cell counting Kit-8 (CCK-8). Cell proliferation was detected by 5-ethynyl-2’-deoxyuridine (EdU) assay. Cell migration was gauged by transwell assay. The downstream effectors of the short peptide were verified using qualitative proteome analysis after immunoprecipitation (IP) experiments. The effect of the short peptide on protein interactions were confirmed by Co-Immunoprecipitation (CoIP) assays. We found that lncRNA LINC00665 encoded an 18-amino acid (aa)-long short peptide (named LINC00665_18aa). LINC00665_18aa suppressed the viability, proliferation, and migration of human MNNG-HOS and U2OS OS cells in vitro and diminished tumor growth in vivo. Mechanistically, LINC00665_18aa impaired the transcriptional activity, nuclear localization, and phosphorylation of cAMP response element-binding protein 1 (CREB1). Moreover, LINC00665_18aa weakened the interaction between CREB1 and ribosomal protein S6 kinase A3 (RPS6KA3, RSK2). Additionally, increased expression of CREB1 reversed the inhibitory effects of LINC00665_18aa on OS cell proliferation and migration. Our findings show that the short peptide LINC00665_18aa exerts a tumor-inhibitory function in OS, providing a new basis for cancer therapeutics through the functions of the short peptides encoded by lncRNAs.


  • Long-term clinical efficacy of cytokine-induced killer cell-based immunotherapy in early-stage esophageal squamous cell carcinoma

    by Yanfen Liu, Zhen Zhang, Yonggui Tian, Dan Wang, Saisai Liu, Lin Li, Na Hao, Guohui Qin, Xuan Zhao, Shuangning Yang, et al.


  • Open Access

    Prediction of Solitary Plasmacytoma of Bone in Elderly Patients: A Nomogram and a Risk Classification System for Overall Survival

    by Xi Zhang, Jiahao Yang, Zhuanhua Tian, Youssef Khabir, Dan Wang

    Background. Solitary plasmacytoma of bone (SPB) is an isolated plasmacytoma of bone origin, most commonly seen in the elderly, with a poor prognosis. So far, there is no precise nomogram to predict the overall survival (OS) of elderly patients with SPB. Our goal is to construct and validate a nomogram for elderly patients with SPB. Methods. This study collected all elderly patients with SPB in the Surveillance, Epidemiology and End Results (SEER) database from 2000 to 2018, and the variables included were age, sex, race, marital status, primary site, grade, stage, surgery, chemotherapy, and radiotherapy. Independent prognostic factors were identified using univariate and multivariate Cox analysis. The nomogram was constructed to predict 1‐, 2‐, and 3‐year OS of elderly patients with SPB. The receiver‐operating characteristic (ROC) and the calibration curves were used to differentiate and calibrate the nomogram. The clinical validity of the nomogram was evaluated by decision curve analysis (DCA). The total OS scores of all elderly SPB patients were calculated and divided into two risk subgroups for comparison. Results. A total of 1837 patients diagnosed with SPB were screened from the SEER database, with a final inclusion of 1180 patients (age ≥ 60 years). Age, radiotherapy, and marital status were significantly correlated with OS. These characteristics were further incorporated into the creation of the nomogram for predicting 1‐, 2‐, and 3‐year OS of elderly patients with SPB. For this predictive model, the area under the ROC curves, calibration curves, and DCA have good performance in terms of differentiation, consistency, and validity, respectively. In addition, patients in the high‐risk group (≥96) had a worse prognosis than those in the low‐risk group (Conclusion. We constructed a nomogram and a risk classification system that could provide an intuitive and effective tool for clinicians to better predict the OS of elderly SPB patients.


  • Efficacy of Early Enteral Immunonutrition on Immune Function and Clinical Outcome for Postoperative Patients With Gastrointestinal Cancer

    by Zhenzhen Luo, Junxia Wang, Zhen Zhang, Hong Li, Lan Huang, Yamin Qiao, Dan Wang, Jingjing Huang, Luwei Guo, Jinbo Liu, et al.

    Background: Nutrition support is crucial for patients with gastrointestinal (GI) cancer after the operation. However, the controversy over the application of parenteral nutrition (PN) and early enteral immunonutrition (EEIN) has no determinate conclusion. Materials and Methods: We compared the effects of PN and EEIN on the postoperative nutrition condition, immune status, inflammation level, long‐term survival, and quality of life of the patients with GI cancer. Seventy‐eight patients were randomly divided into the PN group (n = 44) or EEIN group (n = 34). After an 8‐day nutrition treatment, clinical and immunological parameters were evaluated. Results: The EEIN group had a significantly shorter hospital stay and higher body mass index level on postoperative day 30 than those in the PN group (P < .05). However, total hospital cost and incidences of short‐term postoperative complications had no significant difference (P > .05). The percentages of CD4+, natural killer, and natural killer T lymphocyte cells and the ratio of CD4+/CD8+ in peripheral blood were significantly increased. Compared with the PN group, the EEIN group had a higher expression of activated cell surface markers such as CD27 and CD28. In addition, the secretion of interleukin (IL)–2 and interferon‐γ was significantly higher, and the secretion of tumor necrosis factor–α and IL‐10 was lower. Complication‐free survival in the EEIN group were longer than those in the PN group (P = .04). Conclusion: EEIN is superior to PN in improving nutrition status, enhancing immune function, and elevating quality of life.